Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Securing Each Dose: Reducing Falsification Risk with Dosage Level Authentication

April 01, 2021

Dosage-level authentication provides an added digital layer of security for pharmaceutical companies to ensure their products are not exposed to falsification.

AstraZeneca Confirms Vaccine Efficacy with Phase III Primary Analysis

March 25, 2021

AstraZeneca has released the results of its primary analysis of the Phase III trial data evaluating its COVID-19 vaccine.

Packaging Delivers Micro Dose

March 15, 2021

Smart packaging opens doors to new products for diagnosis and treatment of eye problems.

Merck to Manufacture J&J Vaccine

March 03, 2021

With funding from the federal government, Merck will expand capacity to produce J&J’s COVID-19 vaccine.

Genetic Vaccine Platforms Demonstrate Their Potential

March 03, 2021

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

Slovakia Approves Sputnik V Vaccine

March 03, 2021

RDIF has announced that the Sputnik V vaccine for COVID-19 has been approved in Slovakia under the emergency use authorization procedure.

J&J Vaccine Approved for Emergency Use

March 01, 2021

Distribution of the first one-dose vaccine for COVID-19 to start in early March.

Glatt and Aprecia Collaborate on 3D-Printing for Solid-Dosage Drugs

February 23, 2021

Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.

EC Approves Celltrion Healthcare’s Adalimumab Biosimilar

February 17, 2021

The EC has granted marketing authorization to Celltrion Healthcare for its adalimumab biosimilar, Yuflyma (CT-P17).

Developments Driving Drug Delivery

February 03, 2021

Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.